NRSN — NeuroSense Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875091 ·
Last close
$0.87
Market Cap
$31.48M
52W High
$1.05
52W Low
$0.63
ADV30
135,643
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,028,000 | 166,000 | 2,588,000 |
| Jun 2025 | — | — | — | — | 1,684,000 | 666,000 | 2,203,000 |
| Dec 2024 | 0 | — | -1,771,000 | -1,801,000 | 4,575,000 | 3,378,000 | 1,992,000 |
| Sep 2024 | 0 | — | -2,107,000 | -2,148,000 | 984,000 | 344,000 | 3,802,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-47,785,000
Inventory
—
Receivables
$33,000
ST Investments
—
EBIT TTM
$-3,878,000
Pretax Income TTM
$-3,949,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,085,000 | -11,125,000 | 1,028,000 | 2,588,000 | — | -7,671,000 |
| Dec 2024 | 0 | -9,902,000 | -10,210,000 | 4,575,000 | 1,992,000 | — | -10,135,000 |
| Dec 2023 | 0 | -12,049,000 | -10,107,000 | 3,185,000 | 4,944,000 | — | -8,354,000 |
| Dec 2022 | 0 | -10,554,000 | -10,492,000 | 7,710,000 | 2,091,000 | — | -7,616,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APLM | Apollomics Inc. | $30.94M | $14.09 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $30.80M | $0.76 | — |
| TVRD | Tvardi Therapeutics, Inc. | $32.27M | $3.44 | — |
| BOLD | Boundless Bio, Inc. | $33.02M | $1.47 | — |
| NSRX | Nasus Pharma Ltd | $33.14M | $2.83 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroSense Announces Pricing of Insider-Led PIPE Financing
2026-04-28 18:30 · Yahoo
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
2026-04-06 13:20 · Yahoo
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
2026-04-03 14:02 · Yahoo
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2026-03-31 13:20 · Yahoo
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
2026-03-24 13:00 · Yahoo
/C O R R E C T I O N -- NeuroSense/
2026-03-18 14:44 · Yahoo
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
2026-03-16 15:30 · Yahoo
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
2026-03-09 15:07 · Yahoo
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
2026-02-18 14:05 · Yahoo
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
2026-02-09 14:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.